[Studies on the therapeutics of experimental toxoplasmosis. I. Effect of acetylspiramycin and spiramycin on the intracardiac Toxoplasma multiplication in mice infected with Toxoplasma gondii (author's transl)].
A total of 329 human serum samples were collected from the clinics of internal medicine of Obihiro city and its suburbs and were screened for Toxoplasma antibody level using the latex agglutination microtiter method (LA). Ninety-one (27.7%) were positive, 4 (1.2%) were equivocal and 234 (71.1%) were negative. Positive reactants were highest in the age group of 55-74 years old. A relatively high percentage on positive reactants was observed in patients with accompanying cardiac and cerebral disorders, i.e., 33.3% and 35.6%, respectively. ICR-JCL mice were infected with 10(2) tachyzoites of the S-273 strain of T. gondii intraperitoneally. Chronic cases were obtained from those mice which survived the first infection without any further challenge 1 month later. Therapy was carried out by administering acetylspiramycin or spiramycin per os at a dose of 8 mg/0.5 ml per mouse per day for 30 days. After the end of therapy, brain and heart emulsions were made, and passaged to clean mice and observed for 30 days. Antibody titers were also monitored during the course of treatment using the LA microtiter method. In the acute cases, antibody titers were observed to gradually increase from the end of treatment up to 10 weeks. Antibody titers of the chronic cases were maintained at high levels before the start of treatment and up to its termination. Most of the mice subinoculated with brain emulsions obtained from the acute cases, both in the control and treatment groups, died. However, all of the mice subinoculated with heart emulsions from both treatment groups, survived. In the chronic cases, all mice subinoculated with brain emulsions from all groups died. A few survived the heart passages from both treatment groups, however, they showed very high reactions to the LA microtiter method.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000906:Antibodies / Q000032:analysis; D001921:Brain / Q000469:parasitology; D005260:Female; D006321:Heart / Q000469:parasitology; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008875:Middle Aged; D015572:Spiramycin / Q000031:analogs & derivatives*; D014122:Toxoplasma / Q000276:immunology; D014123:Toxoplasmosis / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D000906:Antibodies; D007933:Leucomycins; C033163:acetylspiramycin; D015572:Spiramycin